Name

Amphista Therapeutics

Legal name

Amphista Therapeutics Limited

Website

https://amphista.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Targeted protein degradation
• Molecular glue degraders
• Biopharmaceutical therapeutics
• Protein degradation platform
• Targeted cancer therapy

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Drug Development and Licensing: Pre-revenue clinical stage biotech developing targeted protein degradation therapeutics. Revenue expected through licensing deals, co-development partnerships, and eventual product commercialization.
2. Strategic Partnerships and Collaborations: The company has existing strategic collaborations with Bristol Myers Squibb and Merck, generating partnership revenue and advancing their technology platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Amphista Therapeutics develops rationally designed Targeted Glue therapeutics, which are bifunctional small molecules that selectively recruit novel E3 ligases (DCAF16, FBXO22, DCAF11) to degrade disease-causing proteins. The lead clinical candidate AMX-883 is an oral DCAF16-dependent BRD9 degrader for acute myeloid leukaemia with FDA IND clearance in June 2026 and a planned Phase 1 trial in H2 2026. The pipeline also includes SMARCA2 degraders for SMARCA4-deficient NSCLC, FBXO22-mediated TEAD degraders for mesothelioma, and CNS-penetrant programs for neurodegeneration, all designed using the proprietary Eclipsys discovery platform.

Product overview

Amphista Therapeutics is developing a portfolio of next-generation Targeted Protein Degradation (TPD) medicines through its proprietary Eclipsys® platform. The company's core technology is the Targeted Glues® approach, which uses rationally designed bifunctional molecules to recruit diverse E3 ligases (DCAF16, FBXO22, DCAF11) beyond traditional cereblon/VHL-based PROTACs. The lead clinical candidate is AMX-883, an orally bioavailable BRD9 degrader for acute myeloid leukaemia entering Phase 1 in H2 2026. The pipeline includes SMARCA2 Targeted Glues for NSCLC and TEAD Targeted Glues for mesothelioma/NSCLC, both targeting candidate selection in H2 2026. The company is also developing CNS-penetrant Targeted Glues for neurodegeneration and has demonstrated compatibility with degrader-antibody conjugates (DACs).

Differentiator

Problem solved

Functional benefit

Brands

• Eclipsys: Amphista's proprietary platform technology for developing Targeted Glue degraders using high-resolution CryoEM, geometric deep learning, advanced folding algorithms and cheminformatics
• Targeted Glue

Products and services

• Eclipsys® Platform Proprietary in-house discovery platform that combines high-resolution CryoEM of ternary complexes, geometric deep learning, advanced folding algorithms, and cheminformatics to rationally design and optimize Targeted Glue degraders. Used internally by Amphista scientists to develop new therapeutic candidates across oncology and neurodegeneration.
• AMX-883 Lead clinical candidate: an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue degrader of BRD9 for the treatment of acute myeloid leukaemia (AML). Achieves near complete BRD9 degradation within 2 hours with exquisite selectivity. FDA IND clearance received in June 2026 with Phase 1 monotherapy dose-escalation trial planned for H2 2026 in relapsed/refractory AML and high-risk MDS patients.
• SMARCA2 Targeted Glues DCAF16-dependent Targeted Glues designed to selectively degrade SMARCA2 in SMARCA4-deficient cancers, primarily non-small cell lung cancer (NSCLC) with potential application to CNS metastasis. Demonstrates >95% SMARCA2 degradation within 4 hours with near complete selectivity over SMARCA4 and intrinsic brain penetrance.
• TEAD Targeted Glues FBXO22-mediated Targeted Glues designed to degrade TEAD transcription factors via a novel aldehyde-mediated degron mechanism. Targets Hippo-pathway driven cancers including mesothelioma and non-small cell lung cancer (NSCLC), with demonstrated synergy in combination with EGFR inhibitors. Achieves >90% degradation within 2 hours sustained at >70% for 72 hours following oral dosing.
• CNS-Penetrant Targeted Glues Early-stage pipeline of orally bioavailable Targeted Glues designed for activity deep within the central nervous system. Targets high-value disease targets with genetic or clinical validation in neurodegeneration, exploiting the intrinsic brain penetration of AMPX TPD warheads to address CNS disorders that conventional PROTACs cannot reach.
• Degrader-Antibody Conjugates (DACs) Platform extension demonstrating that Amphista's Targeted Glue chemistry is compatible with degrader-antibody conjugate approaches, expanding therapeutic opportunities beyond oral small molecule degraders to antibody-targeted delivery modalities.

Quantifiable outcome

• Near complete BRD9 degradation within 2 hours of treatment
• +4 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Three partnerships are on record, tiered strategic and foundational.

• Bristol Myers SquibbstrategicStrategic or Co-development PartnerStrategic collaboration partner with existing partnership for targeted protein degradation research and development.
• MerckstrategicStrategic or Co-development PartnerStrategic collaboration partner with existing partnership for targeted protein degradation research and development.
• University of DundeefoundationalStrategic or Co-development PartnerFounded based on ground-breaking science of Professor Alessio Ciulli of Dundee University. Academic collaboration providing foundational TPD technology platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arvinas: Pioneer in targeted protein degradation with PROTAC technology and multiple clinical-stage assets. Directly comparable as a TPD therapeutics company pursuing novel protein degrader mechanisms against high-value oncology targets, though focused on traditional CRBN/VHL recruitment.
• Foghorn Therapeutics: Direct competitor in chromatin biology and protein degradation with overlapping BRD9 and SMARCA programs. Most comparable peer given direct target overlap (BRD9, SMARCA2/4) and parallel approach to oncology-targeted degraders, providing clear competitive benchmark.
• Monte Rosa Therapeutics: Clinical-stage biotechnology company developing molecular glue degraders (MGDs) for precision oncology and inflammatory diseases. Highly comparable as a molecular glue-focused degrader company with similar mechanism-driven approach to undruggable targets.
• Kymera Therapeutics: Clinical-stage biopharmaceutical company focused on targeted protein degradation using proprietary heterobifunctional degraders. Direct competitor in the TPD space with multiple clinical-stage assets, larger capitalization, and established pharma partnerships.
• Nurix Therapeutics: Clinical-stage biopharmaceutical company developing small molecule therapies that control protein homeostasis through protein degradation and protein stabilization. Direct competitor with DNA-encoded library platform and multiple clinical-stage degrader programs.
• C4 Therapeutics: Clinical-stage biopharmaceutical company developing novel small molecule degraders of cancer-causing proteins. Direct competitor in targeted protein degradation with Torq platform and clinical-stage oncology assets.

Emerging players

• Dunad Therapeutics: Early-stage biopharmaceutical company developing next-generation targeted protein degradation therapies using mono-valent molecular glue degraders. Comparable emerging TPD company with focus on CNS and other undruggable targets.
• Proxygen: Austrian biotech developing molecular glue degraders through proprietary discovery platform. Comparable emerging player in molecular glue space, though earlier stage and focused on target identification through E3 ligase screening.

Broad incumbents

• Bristol Myers Squibb: Major pharmaceutical company and existing strategic collaboration partner with Amphista. Relevant as both a partner validating Amphista's platform and as a broad incumbent developing internal TPD programs that could compete with Amphista's pipeline.
• Novartis: Major pharmaceutical company with Novartis Venture Fund as Amphista investor. Relevant as a broad incumbent with significant internal TPD investment and potential strategic acquirer or partner for Amphista's clinical assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amphista Therapeutics